glaucoma medications

Tracking treatment adherence in newly diagnosed open-angle glaucoma
Tracking treatment adherence in newly diagnosed open-angle glaucomaAn analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.
6 things PCPs should know about glaucomaGlaucoma is a leading cause of blindness, a problem which is made even more serious by the fact that many patients do not notice any symptoms until it is too late to prevent permanent blindness.
To improve compliance in glaucoma patients, keep it simpleNoncompliance with glaucoma medication is a familiar issue. There is no one-size-fits-all solution, but aiming for simplicity, consistency, and stability from the start of treatment could help more patients adhere to their treatment plan.
Topical treatment warning for orbital soft tissue
Topical treatment warning for orbital soft tissueTopical glaucoma drops have potential for causing profound structural soft-tissue changes.
Directly targeting pathology: A novel approach to treating glaucomaRho kinase inhibitors are intriguing in that they work directly on the pathogenic mechanism of abnormally elevated IOP, increased resistance to trabecular outflow.
Generics improve compliance in glaucoma patientsCompliance is a common concern with glaucoma patients, but a study recently published in Ophthalmology found that generic medication may help increase adherence, possibly due to lower cost.
Improving quality of life in glaucoma patientsDavid Friedman, MD, says glaucoma has a major impact on a patient’s quality of life, but shared his tips for treating these concerns.
New glaucoma drugs aim to shake up marketReuters recently reported on a new wave of drugs in development that it says will shake up glaucoma treatments. When the consumer media is giving your patients direct information about eye care, are you ready to answer their questions?
A clinical perspective of neovascular glaucomaNeovascular glaucoma is a potentially devastating ocular consequence of pathologic neovascularization of intraocular tissue. The symptoms include vision loss caused by both the underlying etiology (such as retinal vascular disease) as well as increased intraocular pressure (IOP), often accompanied by corneal edema, hyphema, or vitreous hemorrhage.
Glaucoma drug may help treat diabetesA study recently published in Diabetes Care found that methazolamide (Neptazane, Fera) significantly lowered HbA1C levels in patients with type 2 diabetes.